{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:33:27Z","timestamp":1791113607832,"version":"4.1.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1681\/asn.2013030273","type":"journal-article","created":{"date-parts":[[2013,12,12]],"date-time":"2013-12-12T22:49:47Z","timestamp":1386888587000},"page":"1094-1102","source":"Crossref","is-referenced-by-count":82,"title":["Long-Term Effects of Spironolactone in Peritoneal Dialysis Patients"],"prefix":"10.1681","volume":"25","author":[{"given":"Yasuhiko","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeyuki","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshige","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotake","family":"Kasuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Yuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuaki","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-28-20230208","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.2215\/CJN.04860709","article-title":"Left ventricular mass in chronic kidney disease and ESRD.","volume":"4","author":"Glassock","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R2-28-20230208","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrneph.2010.68","article-title":"Cardiovascular risk in the peritoneal dialysis patient.","volume":"6","author":"Krediet","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"R3-28-20230208","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).","volume":"80","author":"Herzog","year":"2011","journal-title":"Kidney Int"},{"key":"R4-28-20230208","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/j.1523-1755.2004.00530.x","article-title":"Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression.","volume":"65","author":"Zoccali","year":"2004","journal-title":"Kidney Int"},{"key":"R5-28-20230208","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1681\/ASN.V12122759","article-title":"Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study.","volume":"12","author":"London","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R6-28-20230208","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1523-1755.2005.00086.x","article-title":"Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients.","volume":"67","author":"Aoki","year":"2005","journal-title":"Kidney Int"},{"key":"R7-28-20230208","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1523-1755.2005.00072.x","article-title":"Electrocardiographic abnormalities and uremic cardiomyopathy.","volume":"67","author":"Stewart","year":"2005","journal-title":"Kidney Int"},{"key":"R8-28-20230208","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1681\/ASN.V5122024","article-title":"The prognostic importance of left ventricular geometry in uremic cardiomyopathy.","volume":"5","author":"Foley","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"R9-28-20230208","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrneph.2010.191","article-title":"Sudden cardiac death in chronic kidney disease: Epidemiology and prevention.","volume":"7","author":"Shamseddin","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"R10-28-20230208","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R11-28-20230208","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"R12-28-20230208","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms.","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"R13-28-20230208","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study.","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"R14-28-20230208","first-page":"507","article-title":"A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis.","volume":"23","author":"Taheri","year":"2012","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"R15-28-20230208","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/ndt\/17.11.2035","article-title":"Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function.","volume":"17","author":"Hausmann","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"R16-28-20230208","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/ndt\/gfk086","article-title":"Is it time for spironolactone therapy in dialysis patients?","volume":"21","author":"Covic","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R17-28-20230208","first-page":"367","article-title":"Cardiac magnetic resonance imaging in hemodialysis patients.","volume":"22","author":"McGill","year":"2009","journal-title":"J Nephrol"},{"key":"R18-28-20230208","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1744-9987.2012.01143.x","article-title":"An overview of regular dialysis treatment in Japan (as of 31 December 2010).","volume":"16","author":"Nakai","year":"2012","journal-title":"Ther Apher Dial"},{"key":"R19-28-20230208","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1681\/ASN.V1271508","article-title":"Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients.","volume":"12","author":"Zoccali","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R20-28-20230208","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/ndt\/gfp067","article-title":"Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients.","volume":"24","author":"Wang","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R21-28-20230208","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1046\/j.1523-1755.2002.00471.x","article-title":"A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients.","volume":"62","author":"Wang","year":"2002","journal-title":"Kidney Int"},{"key":"R22-28-20230208","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1053\/j.ajkd.2009.02.012","article-title":"The importance of residual kidney function for patients on dialysis: A critical review.","volume":"53","author":"Perl","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R23-28-20230208","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease.","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"R24-28-20230208","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/CIRCULATIONAHA.106.678342","article-title":"Chronic kidney disease: Effects on the cardiovascular system.","volume":"116","author":"Schiffrin","year":"2007","journal-title":"Circulation"},{"key":"R25-28-20230208","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/ki.2009.35","article-title":"Left ventricular hypertrophy in renal disease: Beyond preload and afterload.","volume":"75","author":"Ritz","year":"2009","journal-title":"Kidney Int"},{"key":"R26-28-20230208","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000100106","article-title":"Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis.","volume":"27","author":"Steigerwalt","year":"2007","journal-title":"Am J Nephrol"},{"key":"R27-28-20230208","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.107.109645","article-title":"Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats.","volume":"52","author":"Michea","year":"2008","journal-title":"Hypertension"},{"key":"R28-28-20230208","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/HYPERTENSIONAHA.109.140038","article-title":"Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.","volume":"54","author":"Tian","year":"2009","journal-title":"Hypertension"},{"key":"R29-28-20230208","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/089686080302300106","article-title":"The association of peritoneal transport properties with 24-hour blood pressure levels in CAPD patients.","volume":"23","author":"Tonbul","year":"2003","journal-title":"Perit Dial Int"},{"key":"R30-28-20230208","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: An emerging paradigm in chronic kidney disease.","volume":"79","author":"Bertocchio","year":"2011","journal-title":"Kidney Int"},{"key":"R31-28-20230208","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/ki.2011.505","article-title":"Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: Current concepts and emerging treatment paradigms.","volume":"81","author":"Shavit","year":"2012","journal-title":"Kidney Int"},{"key":"R32-28-20230208","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R33-28-20230208","doi-asserted-by":"crossref","first-page":"F1084","DOI":"10.1152\/ajprenal.00565.2007","article-title":"Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model.","volume":"294","author":"Nishimura","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"R34-28-20230208","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000221063","article-title":"Peritoneal mesothelial cells as a target of local aldosterone action: Upregulation of connective tissue growth factor expression via serum- and glucocorticoid-inducible protein kinase 1.","volume":"32","author":"Okazaki","year":"2009","journal-title":"Kidney Blood Press Res"},{"key":"R35-28-20230208","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1053\/j.ajkd.2004.01.019","article-title":"Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD.","volume":"43","author":"Suzuki","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R36-28-20230208","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0002-9343(01)00642-8","article-title":"Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: An analysis of 25 cases.","volume":"110","author":"Schepkens","year":"2001","journal-title":"Am J Med"},{"key":"R37-28-20230208","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"R38-28-20230208","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000182504","article-title":"Continuous ambulatory peritoneal dialysis - 1981.","volume":"30","author":"Oreopoulos","year":"1982","journal-title":"Nephron"},{"key":"R40-28-20230208","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.ajkd.2005.03.015","article-title":"Hypokalemia in Chinese peritoneal dialysis patients: Prevalence and prognostic implication.","volume":"46","author":"Szeto","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R41-28-20230208","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis.","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R42-28-20230208","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/aje\/kwk053","article-title":"Less subclinical atherosclerosis in Japanese men in Japan than in White men in the United States in the post-World War II birth cohort.","volume":"165","author":"Sekikawa","year":"2007","journal-title":"Am J Epidemiol"},{"key":"R43-28-20230208","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/hr.2012.216","article-title":"The impact of a change in hypertension management guidelines on diuretic use in Japan: Trends in antihypertensive drug prescriptions from 2005 to 2011.","volume":"36","author":"Kohro","year":"2013","journal-title":"Hypertens Res"},{"key":"R44-28-20230208","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0002-9149(99)80703-6","article-title":"Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities).","volume":"75","author":"Woo","year":"1995","journal-title":"Am J Cardiol"},{"key":"R46-28-20230208","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0894-7317(89)80014-8","article-title":"Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.","volume":"2","author":"Schiller","year":"1989","journal-title":"J Am Soc Echocardiogr"},{"key":"R47-28-20230208","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography\u2019s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"R48-28-20230208","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1253\/circj.CJ-11-1369","article-title":"Left ventricular dysfunction assessed by cardiac time interval analysis among different geometric patterns in untreated hypertension.","volume":"76","author":"Takasaki","year":"2012","journal-title":"Circ J"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201405000-00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:23:30Z","timestamp":1786130610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201405000-00028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2013030273","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718206725.793489267","asserted-by":"object"}]},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}